Fixed-dose inotuzumab ozogamicin (INO) combined with Vincristine and Prednisone (VP) regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia (B-ALL): a multi-center, open-label, single-arm, prospective clinical study
Lei Ju, Sifeng Gao, JiLei Zhang, Yuyu Liu, Qiang Song, Lin Dong, Yan Guo, Xuemei Qin, Jie Zou, Chenglu Yuan, Yan Shi, Dexiao Kong, Kaifeng Wang, Qiang Li, Donglin Yang, Qingliang Teng, Erlie Jiang, Jun Peng, Guanchen Bai · 2026
Read Fixed-dose inotuzumab ozogamicin (INO) combined with Vincristine and Prednisone (VP) regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia (B-ALL): a multi-center, open-label, single-arm, prospective clinical study by Lei Ju, Sifeng Gao, JiLei Zhang, Yuyu Liu, Qiang Song, Lin Dong, Yan Guo, Xuemei Qin, Jie Zou, Chenglu Yuan, Yan Shi, Dexiao Kong, Kaifeng Wang, Qiang Li, Donglin Yang, Qingliang Teng, Erlie Jiang, Jun Peng, Guanchen Bai (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13415782.txt.
Description
Lei Ju and a multicenter team test a fixed dose antibody drug as part of first treatment for B cell acute lymphoblastic leukemia, in a 2026 study set out as a letter. Inotuzumab ozogamicin targets CD22 on leukemia cells and was approved for relapsed disease in 2017. Their plan pairs it with vincristine and prednisone for new adult cases.
Those aged 17 and up can join, with or without the Philadelphia gene swap, in two linked trials split by that mark. The antibody is given as one milligram on three days, capped by body size. Clear scans for trace sick cells early on mean long calm, which drives this early use.
Catalog record
| CREATOR | Lei Ju, Sifeng Gao, JiLei Zhang, Yuyu Liu, Qiang Song, Lin Dong, Yan Guo, Xuemei Qin, Jie Zou, Chenglu Yuan, Yan Shi, Dexiao Kong, Kaifeng Wang, Qiang Li, Donglin Yang, Qingliang Teng, Erlie Jiang, Jun Peng, Guanchen Bai |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 16 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |